Short-Acting Insulin Market Report 2026

The short-acting insulin market size has grown strongly in recent years. It will grow from $11.54 billion in 2025 to $12.14 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to high prevalence of diabetes, widespread insulin therapy adoption, hospital-based diabetes management, expansion of insulin access programs, improved diabetes diagnosis rates.

The short-acting insulin market size is expected to see strong growth in the next few years. It will grow to $14.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising type 2 diabetes incidence, increasing insulin dependence, growth in home-based diabetes care, expansion of insulin delivery technologies, rising demand for fast-acting insulin. Major trends in the forecast period include rising demand for post-meal blood glucose control, increasing use of rapid-acting insulin analogues, growing adoption of pre-filled insulin pens, expansion of intensive insulin therapy regimens, increased focus on tight glycemic management.

The growing prevalence of type 1 diabetes is anticipated to drive the expansion of the short-acting insulin market in the coming years. Type 1 diabetes is an autoimmune disorder in which the immune system attacks insulin-producing cells, making lifelong insulin treatment essential. The increase in Type 1 diabetes cases is attributed to a combination of genetic predisposition, environmental influences, and a rise in autoimmune conditions. Short-acting insulin supports the management of type 1 diabetes by enabling rapid regulation of blood glucose levels and closely replicating the body’s natural insulin response. For example, in December 2023, Diabetes Australia, an Australia-based organization focused on diabetes awareness, reported that around 134,000 Australians were living with Type 1 diabetes in 2022, a number that rose to 135,423 in 2023. As a result, the rising prevalence of type 1 diabetes is contributing to the growth of the short-acting insulin market.

Major companies operating in the short-acting insulin space are focusing on developing innovative solutions such as interchangeable rapid-acting insulin biologics to improve glycemic control and allow flexible substitution for people with diabetes. An interchangeable rapid-acting insulin biologic is a biologically derived insulin that acts quickly to reduce post-meal blood glucose levels and is approved by regulators to be substituted for an equivalent insulin product without requiring a new prescription, supporting consistent and adaptable diabetes management. For instance, in July 2025, Biocon Biologics, a U.S.-based biosimilars company headquartered in India and the United States, received FDA approval for Kirsty (insulin aspart-xjhz), the first and only interchangeable rapid-acting insulin aspart in the U.S. Kirsty is a biosimilar to NovoLog (insulin aspart), with clinical and analytical data confirming no meaningful differences in safety, efficacy, purity, or potency, and is available as a 100 units/mL formulation in both a single-use prefilled pen for subcutaneous administration and a multidose vial for subcutaneous and intravenous use, aimed at improving glycemic control in adults and children with diabetes mellitus.

In December 2024, Lupin Limited, an India-based pharmaceutical firm, acquired the Humulin portfolio in India from Eli Lilly & Company for an undisclosed sum. Through this acquisition, Lupin seeks to reinforce its presence in the Indian insulin space by broadening its product offerings with the inclusion of Huminsulin from Eli Lilly and Company. Eli Lilly and Company is a US-based pharmaceutical organization focused on insulin therapies, including short-acting insulin products.

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited.

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the short-acting insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the short-acting insulin market by increasing the cost of importing active pharmaceutical ingredients, recombinant insulin, cartridges, and pre-filled pen components used in diabetes treatment. Vials, cartridges, and pen-based insulin products are most affected, particularly in North America and Asia-Pacific where global insulin supply chains are heavily utilized. Hospital pharmacies and retail pharmacies face higher procurement and distribution costs. However, tariffs are encouraging domestic insulin manufacturing and local fill-and-finish operations, supporting long-term supply stability and pricing control.

The short-acting insulin market research report is one of a series of new reports that provides short-acting insulin market statistics, including short-acting insulin industry global market size, regional shares, competitors with a short-acting insulin market share, detailed short-acting insulin market segments, market trends and opportunities, and any further data you may need to thrive in the short-acting insulin industry. This short-acting insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Short-acting insulin is a form of insulin used to manage blood glucose levels during or following meals. It starts acting within 30 minutes to 1 hour, reaches its peak effect at about 2-3 hours, and remains effective for 4-6 hours. Short-acting insulin is essential for controlling blood sugar by helping glucose enter the body’s cells, where it is utilized for energy, especially after food intake.

The primary formulation types of short-acting insulin include regular insulin and rapid-acting insulin. Regular insulin is a fast-acting insulin used to manage blood glucose levels in individuals with diabetes and is usually administered prior to meals. These formulations are offered in multiple dosage forms, such as vials, pre-filled pens, and cartridges, and can be delivered via subcutaneous or intravenous routes. It is prescribed for patients with both type 1 and type 2 diabetes and is distributed through various channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The short-acting insulin market consists of sales of human insulin, analogue insulin, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.